Filing Analysis
Stereotaxis, Inc. reported the results of its Annual Meeting of Shareholders held on May 14, 2026, where shareholders voted on director elections, auditor ratification, and executive compensation.
📋 Key Facts
- The Annual Meeting was held on May 14, 2026, with 65.34% of the total voting power represented.
- Three Class I directors, David Benfer, Dr. Arun Menawat, and Dr. Myriam Curet, were elected to serve until the 2029 Annual Meeting.
- Shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026 with 79,036,638 votes in favor.
- Executive compensation was approved on a non-binding advisory basis with 52,143,334 votes in favor.
- Total outstanding voting power included 97,477,538 shares of common stock and 23,705,445 votes from Series A Convertible Preferred Stock.
Stereotaxis, Inc. reported its financial results for the first quarter ended March 31, 2026. The filing is a routine disclosure of quarterly performance and does not contain any immediate material changes to corporate structure or operations.
📋 Key Facts
- The company issued its Q1 2026 earnings press release on May 12, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The filing includes Exhibit 99.1, which contains the full earnings press release.
- The report was signed by Kimberly R. Peery, Chief Financial Officer.
Stereotaxis (STXS) entered into a Share Sale Agreement to acquire 100% of Robocath, a French robotic medical technology company, for $20 million upfront and up to $25 million in performance-based earnouts. The transaction is contingent upon Stereotaxis completing a debt restructuring with its lenders and obtaining French regulatory clearance.
🚩 Red Flags
- The acquisition is contingent on Stereotaxis completing a debt restructuring, indicating potential balance sheet stress.
- Stereotaxis is providing interim financing to the target before the deal closes, assuming operational risk for Robocath.
- The deal requires clearance from the French Ministry of Economy, introducing geopolitical/regulatory risk.
- Potential for significant dilution through the issuance of common stock and 'pre-funded' warrants.
📋 Key Facts
- Upfront consideration of $20.0 million payable in cash, stock (valued at $2.00 per share), or a combination.
- Contingent earnout payments of up to $25 million: $10 million for US FDA regulatory approval and $15 million for commercial sales milestones.
- Stereotaxis is providing interim financing to Robocath via bonds, with an initial expected amount of approximately €1.3 million.
- Closing is subject to a mandatory debt restructuring transaction by Stereotaxis and its lenders.
- The acquisition is expected to close in July 2026, with an 'end date' of December 31, 2026.
- Issuance of stock is subject to a 19.9% NYSE American Share Cap unless stockholder approval is obtained.
Stereotaxis, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. The filing serves as a formal notice of the earnings press release issued on March 9, 2026.
📋 Key Facts
- The report was filed on March 9, 2026, covering the period ending the same day.
- Financial results for the 2025 fourth quarter and full year were disclosed via an earnings press release.
- The information was filed under Item 2.02 (Results of Operations and Financial Condition).
- Exhibit 99.1 contains the detailed Earnings Press Release.